Expert Ratings for Harmony Biosciences
Portfolio Pulse from Benzinga Insights
Harmony Biosciences (NASDAQ:HRMY) has received 8 bullish, 2 somewhat bullish, and 1 bearish rating from analysts in the last quarter. The average price target is $59.0, indicating an upside from the current price of $33.13. This average has increased by 9.26% from the previous average price target of $54.00.
September 25, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harmony Biosciences has received mostly bullish ratings from analysts, with an average price target indicating potential upside.
The majority of analysts have given Harmony Biosciences a bullish rating, indicating a positive outlook for the stock. The average price target is significantly higher than the current price, suggesting potential upside. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100